Abstract 1504: Fusobacterium-driven epithelial-stromal remodeling in CRC

Abstract Background: Fusobacterium nucleatum is recognized as a key microbial factor accelerating colorectal cancer (CRC) progression. However, the cellular and molecular mechanisms underlying its impact on the tumor microenvironment (TME) are not yet fully understood. Methods: We performed single-cell RNA sequencing on specimens from 39 CRC patients. Samples were stratified into Fusobacterium-positive (Fuso-pos; n=14) and Fusobacterium-negative (Fuso-neg; n=25) groups using a 1% microbial abundance cutoff. Comparative analyses were conducted across the stromal and epithelial compartments to investigate microbe-associated transcriptional programs, pathway activation, and fibroblast-epithelial interactions. Results: CRC tumors with high Fusobacterium abundance exhibited coordinated remodeling of both stromal and epithelial landscapes. Fibroblasts from Fuso-pos samples showed enhanced interferon-driven inflammatory activity and mesenchymal transition, accompanied by a marked expansion of a specific myofibroblastic cancer-associated fibroblast (myCAF) subtype. In the epithelial compartment, Fuso-pos tumors showed increased genomic instability, elevated stemness, and upregulation of CMS4-related signatures. Gene module analyses demonstrated a strong increase in epithelial-mesenchymal transition-related module in epithelial cells upon Fusobacterium infection, which correlated significantly with the myCAF abundance. Analysis of bulk RNA-seq data further confirmed that a higher proportion of the deconvoluted myCAF subtype was associated with unfavorable clinical outcomes. Mechanistically, Fuso-pos tumor cells showed increased SHH expression, while the myCAFs exhibited high expression of Hedgehog signaling components, indicating augmented epithelial-stromal Hedgehog signaling. Conclusions: These findings suggest that Fusobacterium infection in CRC promotes epithelial-stromal signaling through the SHH-Hedgehog axis, contributing to CRC progression. It may represent a therapeutically targetable component of the TME in Fusobacterium-associated CRC. Acknowledgments: The authors gratefully acknowledge support from the following funding sources: a grant of the Korea Health Technology R Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1504.